A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ELIANA
- Sponsors Novartis; Novartis Pharmaceuticals
- 20 Feb 2018 Planned End Date changed from 3 Mar 2022 to 26 Nov 2021.
- 20 Feb 2018 Planned primary completion date changed from 15 Feb 2018 to 31 Jul 2018.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History